Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease Network WORLD Symposium

Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease
Network WORLD Symposium

CRANBURY, N.J., Jan. 30, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics
(Nasdaq:FOLD) today announced that three oral presentations and five posters
highlighting its development programs for lysosomal storage diseases will be
included at the 10^th Annual Lysosomal Disease Network WORLD Symposium (LDN
WORLD), to be held February 10-14, 2014 in San Diego, CA.

Oral Platform Presentations:

Pompe Disease:

  *Chemical Conjugation of Targeting Peptide to ERTs Improve Receptor Binding
    and Substrate Clearance in Mouse Models of Disease – Hung Do, PhD, Amicus
    Therapeutics, Inc. (Wednesday, February 12 at 2:45 p.m. PT)

Fabry Disease:

  *Phase 3 Study (FACETS) of Migalastat HCl for Fabry Disease: Post hoc GLA
    Mutation-Based Identification of Subjects Likely to Show a Drug Effect –
    Jeffrey P. Castelli, PhD, Amicus Therapeutics, Inc. (Thursday, February 13
    at 11:15 a.m. PT)

Gaucher Disease:

  *Glucosylceramide and Glucosylsphingosine Quantitation by Liquid
    Chromatography-Tandem Mass Spectrometry to Enable Studies of Neuronopathic
    Gaucher Disease – Rick Hamler, Amicus Therapeutics, Inc. (Tuesday,
    February 11 at 10:30 a.m. PT)

Posters: Tuesday, February 11 - Thursday, February 13, 4:00-6:00 p.m. PT

Pompe Disease:

  *Chemical Conjugation of Targeting Peptide to ERTs Improve Receptor Binding
    and Substrate Clearance in Mouse Models of Disease – Russell Gotschall,
    Amicus Therapeutics, Inc.
    
  *Subcutaneous Administration of Recombinant Human Acid Alpha-Glucosidase
    Co-formulated with the Pharmacological Chaperone AT2220 Leads to Lysosomal
    Uptake of rhGAA and Glycogen Reduction in Disease-relevant Tissues of
    Pompe Mice – Yi Lun, Amicus Therapeutics, Inc.
    
  *Strategy to Assess the Effect of Duvoglustat Co-administered with
    Alglucosidase Alfa Infusion on the Immune Response to Enzyme Replacement
    Therapy for Pompe Disease – Xiaoyang Wu, Amicus Therapeutics, Inc.
    
  *Liquid Chromatography-Tandem Mass Spectrometry Determination of AT2220 in
    Rodent Plasma and Tissues – Leo B. Dungan, Amicus Therapeutics, Inc.

Fabry Disease:

  *Phase 3 Study (FACETS) of Migalastat HCl for Fabry Disease: Post hoc GLA
    Mutation-Based Identification of Subjects Likely to Show a Drug Effect –
    Elfrida R. Benjamin, Amicus Therapeutics, Inc.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the
forefront of therapies for rare and orphan diseases. The Company is developing
novel, first-in-class treatments for a broad range of human genetic diseases,
with a focus on delivering new benefits to individuals with lysosomal storage
diseases. Amicus' lead programs include the small molecule pharmacological
chaperones migalastat HCl as a monotherapy and in combination with enzyme
replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in
combination with ERT for Pompe disease.

CONTACT: Investors/Media:
         Sara Pellegrino
         spellegrino@amicusrx.com
         (609) 662-5044
 
Press spacebar to pause and continue. Press esc to stop.